{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:03:41Z","timestamp":1790697821020,"version":"4.1.0"},"reference-count":19,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of VitreoRetinal Diseases"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:p>\n                    <jats:bold>Purpose:<\/jats:bold>\n                    To describe 3 cases of intraocular inflammation (IOI) in patients who received faricimab and high-dose aflibercept in consecutive order.\n                    <jats:bold>Methods:<\/jats:bold>\n                    Retrospective case review.\n                    <jats:bold>Results:<\/jats:bold>\n                    Three patients, 2 with neovascular age-related macular degeneration (nAMD) and 1 with central retinal vein occlusion (CRVO), transitioned from 2 mg aflibercept to either faricimab (in cases 1 and 2) or high-dose aflibercept (in case 3) due to persistent disease activity. In all cases, contemporary medication provided minimal effect. Subsequently, patients in cases 1 and 2 were switched to high-dose aflibercept at their next visit, and the patient in case 3 was switched to faricimab. On follow-up, the disease worsened in all 3 cases. Each patient returned to their previous drug. Shortly after, each patient developed an episode of IOI.\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    Patients receiving different high-dose or longer-acting agents in short order may be at risk for developing antidrug antibodies and IOI.\n                  <\/jats:p>","DOI":"10.1177\/24741264251365391","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T12:11:04Z","timestamp":1756123864000},"page":"871-875","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Sterile Intraocular Inflammation in Patients Receiving Both Faricimab and High-Dose Aflibercept in Consecutive Order"],"prefix":"10.1177","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0466-3824","authenticated-orcid":false,"given":"Emmanuel A.","family":"Dwomoh","sequence":"first","affiliation":[{"name":"Frank H. Netter MD School of Medicine, Quinnipiac University, Hamden, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1505-2079","authenticated-orcid":false,"given":"Anisa","family":"Prasad","sequence":"additional","affiliation":[{"name":"Frank H. Netter MD School of Medicine, Quinnipiac University, Hamden, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tavish","family":"Nanda","sequence":"additional","affiliation":[{"name":"Retina Consultants P.C., Hartford, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,8,25]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1177\/2040622312446007"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2023.2421"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00010-1"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00063-1"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2024.0530"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-021-00307-7"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000001493"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0000000000000154"},{"key":"e_1_3_2_10_2","unstructured":"Patterson Toby. \u201cVABYSMO\u00ae (Faricimab-SVOA) New Warnings And .\u2004.\u2004.\u201d Subject: VABYSMO\u00ae (faricimab-svoa) New Warnings and Precautions: Retinal Vasculitis and\/or Retinal Vascular Occlusion. November 2023. Accessed February 1 2025. https:\/\/www.gene.com\/download\/pdf\/Vabysmo_DHCP_Important_Drug_Warning_2023-11-03.pdf"},{"key":"e_1_3_2_11_2","unstructured":"Bayer P. A study to learn how well a higher amount of aflibercept given as an injection into the eye works and how safe it is in people with reduced vision due to swelling in the macula central part of the retina caused by a blocked vein in the retina (Macula Edema Secondary to Retinal Vein Occlusion) (QUASAR). Clinicaltrials.gov. January 6 2025. Accessed February 1 2025. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05850520"},{"key":"e_1_3_2_12_2","unstructured":"Iapoce C. Aflibercept 8 mg for RVO hits primary endpoint in phase 3 quasar trial. HCP Live. January 9 2025. Accessed February 1 2025. https:\/\/www.hcplive.com\/view\/aflibercept-8-mg-for-rvo-hits-primary-endpoint-in-phase-3-quasar-trial"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1177\/24741264231220224"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1177\/2474126420975303"},{"key":"e_1_3_2_15_2","unstructured":"VABYSMO. Highlights of prescribing information .\u2004.\u2004. - Genentech. HIGHLIGHTS OF PRESCRIBING INFORMATION. 2022. Accessed February 1 2025. https:\/\/www.gene.com\/download\/pdf\/vabysmo_prescribing.pdf"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.13.11.13"},{"key":"e_1_3_2_17_2","unstructured":"Food and Drug Administration HHS. The clinical evaluation of Qt\/QTc interval prolongation and .\u2004.\u2004. international conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. 2005. Accessed February 2 2025. https:\/\/database.ich.org\/sites\/default\/files\/E14_Guideline.pdf"},{"key":"e_1_3_2_18_2","unstructured":"FDA. Guidance for industry: statistical approaches to establishing bioequivalence. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). 2001. Accessed February 2 2025. https:\/\/www.fda.gov\/downloads\/drugs\/guidances\/ucm070244.pdf"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.11.021"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.08.008"}],"container-title":["Journal of VitreoRetinal Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24741264251365391","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/24741264251365391","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24741264251365391","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:24:20Z","timestamp":1790695460000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/24741264251365391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,25]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1177\/24741264251365391"],"URL":"https:\/\/doi.org\/10.1177\/24741264251365391","relation":{},"ISSN":["2474-1264","2474-1272"],"issn-type":[{"value":"2474-1264","type":"print"},{"value":"2474-1272","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,25]]}}}